Global Chronic Spontaneous Urticaria Drug Treatment Market Growth (Status and Outlook) 2024-2030

Global Chronic Spontaneous Urticaria Drug Treatment Market Growth (Status and Outlook) 2024-2030

Chronic spontaneous urticaria (CSU), also known as chronic idiopathic urticaria, is defined as the presence of urticaria most of the time during a week and this condition lasts for 6 weeks or more. About 40% of patients are accompanied by angioedema. The standard treatment for CSU is mainly second-generation H1 antihistamines, often at higher than conventional doses, combined with H2 antihistamines and leukotriene modulators.

The global Chronic Spontaneous Urticaria Drug Treatment market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.

LPI (LP Information)' newest research report, the “Chronic Spontaneous Urticaria Drug Treatment Industry Forecast” looks at past sales and reviews total world Chronic Spontaneous Urticaria Drug Treatment sales in 2022, providing a comprehensive analysis by region and market sector of projected Chronic Spontaneous Urticaria Drug Treatment sales for 2023 through 2029. With Chronic Spontaneous Urticaria Drug Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Chronic Spontaneous Urticaria Drug Treatment industry.

This Insight Report provides a comprehensive analysis of the global Chronic Spontaneous Urticaria Drug Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Chronic Spontaneous Urticaria Drug Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Chronic Spontaneous Urticaria Drug Treatment market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Chronic Spontaneous Urticaria Drug Treatment and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Chronic Spontaneous Urticaria Drug Treatment.

CSU is a chronic inflammatory skin disease characterized by the sudden onset of hives and/or deep swelling of the skin. Despite standard of care treatments, patients with CSU often experience symptoms such as persistent itching or burning sensations that can be debilitating and significantly impact quality of life. Swelling usually occurs on the face, hands, and feet and can also affect the throat and upper respiratory tract. CSU is commonly treated with antihistamines, but in patients with limited available treatment options, the condition remains uncontrolled in up to 50% of patients.

This report presents a comprehensive overview, market shares, and growth opportunities of Chronic Spontaneous Urticaria Drug Treatment market by product type, application, key players and key regions and countries.

Segmentation by Type:
Antihistamine
Dupixent
Other

Segmentation by Application:
Children
Adult

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Segmentation by Type:
Antihistamine
Dupixent
Other

Segmentation by Application:
Children
Adult

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Mylan N. V.
Sanofi
GlaxoSmithKline
Bayer
Merck
Aurobindo Pharma
Hikma Pharmaceuticals
WOCKHARDT
AbbVie, Inc.
Cipla Inc.
F. Hoffmann La Roche Ltd.
Teva Pharmaceutical Industries, Ltd.
Pfizer, Inc.
Novartis AG
Eli Lilly and Company
Allergan
Lupin

Please note: The report will take approximately 2 business days to prepare and deliver.